Get the Stockscreener App
1.60
1.91%
0.03
After Hours:
1.61
0.01
+0.63%
Pacific Biosciences Of California Inc stock is traded at $1.60, with a volume of 4.33M.
It is up +1.91% in the last 24 hours and up +20.30% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.57
Open:
$1.52
24h Volume:
4.33M
Relative Volume:
0.64
Market Cap:
$483.20M
Revenue:
$160.01M
Net Income/Loss:
$-546.38M
P/E Ratio:
-0.8719
EPS:
-1.835
Net Cash Flow:
$-118.92M
1W Performance:
+8.84%
1M Performance:
+20.30%
6M Performance:
-8.05%
1Y Performance:
+25.98%
1-Day Range:
$1.52
$1.635
1-Week Range:
$1.31
$1.635
52-Week Range:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.60 | 474.14M | 160.01M | -546.38M | -118.92M | -1.835 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
PacBio, Covaris develop workflow for FFPE tissue sequencing By Investing.com - Investing.com Canada
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples - marketscreener.com
Archived tumor samples gain long-read DNA workflow with 60% phasing - Stock Titan
Pacific Biosciences of California fosters connections and momentum at PacBioPRISM event - Traders Union
PACB Maintained by Barclays -- Price Target Lowered to $1.00 - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1 - Moomoo
Pacific Biosciences (PACB) Garnering Attention Amid Involvement in Trillion Gene Atlas Program - Insider Monkey
Pacific Biosciences of California introduces expanded long-read assay to streamline clinical workflows - Traders Union
Market Pulse: Can Pacific Biosciences of California Inc reach all time highs this yearQuarterly Investment Review & Safe Capital Allocation Plans - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - TradingView — Track All Markets
How The PacBio (PACB) Story Is Shifting Between Long Term Potential And Near Term Risks - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California unveils step-by-step HiFi sequencing process leveraging Revio and Vega platforms - Traders Union
Director Christopher Gibson receives options and RSUs at Pacific Biosciences (PACB) - Stock Titan
Pacific Biosciences of California unveils SPRQ-Nx chemistry to streamline cancer testing workflows - Traders Union
Pacific Biosciences of California Inc (MEX:PACB) Stock Price, Trades & News - GuruFocus
Ontario-Based DNAstack Leads Sovereign AI for Genomics and Health with Goal of Making Canadians Healthier and Reducing Strain on our Healthcare System - marketscreener.com
PacBio HiFi WGS resolves hidden disease-linked structural variants in diverse populations - Traders Union
Fundamentals Check: Will Pacific Biosciences of California Inc outperform tech stocksWeekly Trend Summary & Reliable Entry Point Alerts - baoquankhu1.vn
MEX:PACB EV-to-OCF: -7.12 | Modestly Undervalued - GuruFocus
Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained - Bitget
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why - Yahoo Finance
Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.
Pacific Biosciences of California launches HiFi sequencing workshop at AACR26 for cancer genomics - Traders Union
Pacific Biosciences of California Inc (P09.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Pacific Biosciences of California Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Pacific Biosciences of California traces DNA sequencing evolution from Sanger to HiFi platforms - Traders Union
Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes - Stock Titan
Pacific Biosciences of California Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView — Track All Markets
Pacific Biosciences of California expands HiFi WGS and targeted panels to detect hidden cancer variants - Traders Union
Pacific Biosciences of California, Inc. (PACB) latest stock news and headlines - Yahoo Finance Singapore
Trade Report: How does Pacific Biosciences of California Inc compare to its peersMarket Growth Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
[144] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing - Stock Titan
Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today - Bitget
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Yahoo Finance
PACB PE Ratio & Valuation, Is PACB Overvalued - Intellectia AI
Pacific Biosciences of California unveils oncology workflow solutions at industry event - Traders Union
Returns Recap: Will Pacific Biosciences of California Inc outperform during market rallies2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024 - 富途牛牛
Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape - AD HOC NEWS
Stock Report: Can Pacific Biosciences of California Inc reach all time highs this year2026 Final Week & Real-Time Stock Movement Alerts - baoquankhu1.vn
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note - finance.yahoo.com
Vanguard amendment shows 0 PACB shares after realignment (PACB) - Stock Titan
Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider - Bitget
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - MSN
PacBio Secures Agreement with Basecamp Research for Trillion Gene Atlas Project - Bitget
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):